About Servier Canada
Servier Canada is committed to the investment in research and development and was proud to join Canada's Research Based Pharmaceutical Companies (Rx&D) in 1995. In 1998, it established its Canadian International Centre for Therapeutic Research within Servier Canada Inc. In 2003, Servier celebrated 25 years of existence in Canada and the following – more... year opened its first Ontario office in Mississauga to accommodate its continued growth and expansion.
Servier's Research & Development pipeline is extremely healthy having the potential to submit one product for license every year for the next 10 years. With a current clinical research staff of over twenty and significant plans for growth, Servier is continuing a program of rapid expansion and investment into the future in Canada. The Canadian International Centre for Therapeutic Research is responsible for conducting Phase I, II & III clinical trials in Canada with the objective of bringing-to-market new Servier pharmaceuticals.
Over the last five years, SCI has grown substantially and sales are forecasted to reach approximately $113 million by the end of 2009. The number of people employed has risen steadily over this period, a trend that is anticipated to continue. The sales force has grown from 50 field-based personnel spread across the country in seven regions to an excess of 165 across 15 regions. At the same time, Servier has maintained its reputation throughout as being among one of the most professional and scientific-based pharmaceutical companies in Canada.
Looking forward to the future, Servier Canada and the whole Servier Research Group is set for dramatic growth over the next 10 years. From a product portfolio focused on Cardiovascular and Diabetes, Servier will not only have some innovative new products in both of these therapeutic fields, but will enter at least 3 new therapeutic fields in the coming years. In the near future, Servier Canada will make available for patients a portfolio consisting of new and existing products for: hypertension, the prevention of cardiovascular events, type 2 diabetes, depression and mild cognitive impairment.
In FRANCE, success has been spectacular. Currently the second largest French pharmaceutical company worldwide, it is also the largest privately owned and the second largest exporter of pharmaceutical products. In people terms, the work force now totals some 5,000 employees of whom one in four is actively engaged in the research and development of new compounds.
INTERNATIONALLY, the Company's expansion has been equally impressive. Currently represented in more than 140 countries, it has achieved consistently high growth especially throughout the last decade. The company has registered 30 new drugs in 30 years and specifically in the last ten years. The reason for this success is three-fold: firstly, one of the world's highest ratios of investment in research and development; secondly, an enviable reputation for product innovation; thirdly, the motivation, commitment and professionalism of the Company's personnel are second to none. – less – More from ZoomInfo »
Servier Canada Employer Reviews
Working at Servier Canada
